Company profile: Siren Biotechnology
1.1 - Company Overview
Company description
- Provider of AAV immuno-gene therapies that combine AAV gene therapy and cytokine immunotherapy into a single modality for solid tumors, including brain and eye cancers. Its approach delivers engineered cytokines directly to tumors to activate immune responses and destroy cancer cells.
Products and services
- Universal AAV Immuno-Gene Therapy for Cancer: AAV-based modality merging gene therapy and cytokine immunotherapy into one treatment for solid tumors
- AAV Immuno-Gene Therapy: AAV-based therapy targeting brain and eye cancers, delivering engineered cytokines to tumors to activate local immune responses and drive selective cancer cell destruction
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Siren Biotechnology
MolecularMD
HQ: United States
Website
- Description: Provider of specialty molecular diagnostics products and services for oncology, supporting clinical development and commercialization of cancer therapies. Offers tests to enable appropriate selection, monitoring, and management of patients treated with molecularly targeted cancer therapies, incorporating both gold-standard and innovative assay technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MolecularMD company profile →
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carrick Therapeutics company profile →
MDNA Life Sciences
HQ: United States
Website
- Description: Provider of proprietary, blood-based diagnostic tests leveraging mitochondrial DNA to improve early disease detection, diagnosis, treatment, prognosis and monitoring. Offerings include the Mitomic Prostate Test (3.4 kb deletion to assess significant prostate cancer risk and aid biopsy decisions) and Mitomic Endometriosis Test (8.7 kb deletion to reduce diagnostic delays), powered by Mitomic Technology to detect disease-specific mtDNA biomarkers with high sensitivity and specificity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDNA Life Sciences company profile →
Hybrigenics
HQ: France
Website
- Description: Provider of bioinformatics platforms to identify, validate, and inhibit protein interactions to develop cancer therapeutics; a biopharmaceutical company focused on R&D of new targets and therapies against cancer, researching deubiquitinating enzymes (DUBs), and having stopped development of inecalcitol, a vitamin D receptor agonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrigenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Siren Biotechnology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Siren Biotechnology
2.2 - Growth funds investing in similar companies to Siren Biotechnology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Siren Biotechnology
4.2 - Public trading comparable groups for Siren Biotechnology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →